384 related articles for article (PubMed ID: 8462769)
41. Administration of vanadyl sulfate by gavage does not normalize blood glucose levels in streptozotocin-induced diabetic rats.
Domingo JL; Sanchez DJ; Gomez M; Llobet JM; Corbella J
Res Commun Chem Pathol Pharmacol; 1992 Mar; 75(3):369-72. PubMed ID: 1509205
[TBL] [Abstract][Full Text] [Related]
42. Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats.
Li M; Ding W; Smee JJ; Baruah B; Willsky GR; Crans DC
Biometals; 2009 Dec; 22(6):895-905. PubMed ID: 19404749
[TBL] [Abstract][Full Text] [Related]
43. Lack of in vivo effect of vanadium on GLUT4 translocation in white adipose tissue of streptozotocin-diabetic rats.
Cam MC; Brownsey RW; Rodrigues B; McNeill JH
Metabolism; 2001 Jun; 50(6):674-80. PubMed ID: 11398144
[TBL] [Abstract][Full Text] [Related]
44. Vanadyl treatment normalizes submandibular salivary gland insulin-like immunoreactivity in streptozotocin-diabetic rats.
Deville de Périère D; Poucheret P; Egea JC; Gross R; Masiello P; Cros G; Serrano JJ; Ribes G
Horm Metab Res; 1998 Mar; 30(3):150-2. PubMed ID: 9566858
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemistry, histopathology, and biomarker studies of swertiamarin, a secoiridoid glycoside, prevents and protects streptozotocin-induced β-cell damage in Wistar rat pancreas.
Dhanavathy G
J Endocrinol Invest; 2015 Jun; 38(6):669-84. PubMed ID: 25770453
[TBL] [Abstract][Full Text] [Related]
46. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats.
Cam MC; Faun J; McNeill JH
Metabolism; 1995 Mar; 44(3):332-9. PubMed ID: 7885278
[TBL] [Abstract][Full Text] [Related]
47. Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulfate.
Willsky GR; Chi LH; Liang Y; Gaile DP; Hu Z; Crans DC
Physiol Genomics; 2006 Aug; 26(3):192-201. PubMed ID: 16684804
[TBL] [Abstract][Full Text] [Related]
48. Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy.
Anand-Srivastava MB; McNeill JH; Yang XP
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):113-9. PubMed ID: 8927025
[TBL] [Abstract][Full Text] [Related]
49. Quantitative Assessment of Proliferative Effects of Oral Vanadium on Pancreatic Islet Volumes and Beta Cell Numbers of Diabetic Rats.
Pirmoradi L; Noorafshan A; Safaee A; Dehghani GA
Iran Biomed J; 2016; 20(1):18-25. PubMed ID: 26459400
[TBL] [Abstract][Full Text] [Related]
50. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies.
Goldfine AB; Patti ME; Zuberi L; Goldstein BJ; LeBlanc R; Landaker EJ; Jiang ZY; Willsky GR; Kahn CR
Metabolism; 2000 Mar; 49(3):400-10. PubMed ID: 10726921
[TBL] [Abstract][Full Text] [Related]
51. Effects of sodium tungstate and vanadyl sulphate on the liberation of prostanoids of the mesenteric vascular bed in diabetic rats.
Lee HJ; Peredo HA; Cantú SM; Donoso AS; Puyó AM; Choi MR
Clin Investig Arterioscler; 2018; 30(6):249-257. PubMed ID: 29887329
[TBL] [Abstract][Full Text] [Related]
52. Antihyperglycemic and insulin secretory activity of Costus pictus leaf extract in streptozotocin induced diabetic rats and in in vitro pancreatic islet culture.
Gireesh G; Thomas SK; Joseph B; Paulose CS
J Ethnopharmacol; 2009 Jun; 123(3):470-4. PubMed ID: 19501280
[TBL] [Abstract][Full Text] [Related]
53. Effects of vanadyl sulfate on kidney in experimental diabetes.
Yanardag R; Bolkent S; Karabulut-Bulan O; Tunali S
Biol Trace Elem Res; 2003 Oct; 95(1):73-85. PubMed ID: 14555801
[TBL] [Abstract][Full Text] [Related]
54. Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats.
Thompson KH; McNeill JH
Res Commun Chem Pathol Pharmacol; 1993 May; 80(2):187-200. PubMed ID: 8100638
[TBL] [Abstract][Full Text] [Related]
55. Long-term antidiabetic activity of vanadyl after treatment withdrawal: restoration of insulin secretion?
Cros GH; Cam MC; Serrano JJ; Ribes G; McNeill JH
Mol Cell Biochem; 1995 Dec 6-20; 153(1-2):191-5. PubMed ID: 8927038
[TBL] [Abstract][Full Text] [Related]
56. Oral tungstate treatment improves only transiently alteration of glucose metabolism in a new rat model of type 2 diabetes.
Fierabracci V; De Tata V; Pocai A; Novelli M; Barberà A; Masiello P
Endocrine; 2002 Nov; 19(2):177-84. PubMed ID: 12588048
[TBL] [Abstract][Full Text] [Related]
57. Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats.
Feigh M; Hjuler ST; Andreassen KV; Gydesen S; Ottosen I; Henriksen JE; Beck-Nielsen H; Christiansen C; Karsdal MA; Henriksen K
Eur J Pharmacol; 2014 Aug; 737():91-6. PubMed ID: 24858364
[TBL] [Abstract][Full Text] [Related]
58. Oral selenate improves glucose homeostasis and partly reverses abnormal expression of liver glycolytic and gluconeogenic enzymes in diabetic rats.
Becker DJ; Reul B; Ozcelikay AT; Buchet JP; Henquin JC; Brichard SM
Diabetologia; 1996 Jan; 39(1):3-11. PubMed ID: 8720597
[TBL] [Abstract][Full Text] [Related]
59. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
60. Effect of bis[curcumino]oxovanadium complex on non-diabetic and streptozotocin-induced diabetic rats.
Majithiya JB; Balaraman R; Giridhar R; Yadav MR
J Trace Elem Med Biol; 2005; 18(3):211-7. PubMed ID: 15966569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
